EPO and diabetes mellitus: In the present study, we aimed to examine precisely the effects of the SGLT2 inhibitor canagliflozin on erythropoiesis by measuring erythropoiesis parameters, including serum EPO concentration, kidney function parameters, and other metabolic parameters in type 2 diabetes mellitus patients with renal anemia, who are treated with renin-angiotensin system inhibitors.